Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido (NCT00331214) | Clinical Trial Compass
CompletedPhase 3
Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido
United States, Australia, Canada533 participantsStarted 2002-06
Plain-language summary
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in surgically menopausal women who are taking estrogen therapy.
Who can participate
Age range
20 Years – 70 Years
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Be 20-70 years old and in generally good health
. Have undergone hysterectomy and removal of both ovaries at least 6 months prior to screening
. Be receiving a stable dose of estrogen replacement therapy for at least 3 months prior to screening with the intention of maintaining that regimen.
. Be, in her own judgment, in a stable monogamous sexual relationship that is perceived to be secure and communicative, for at least one year prior to study entry.
. Meet the criteria for having hypoactive sexual desire disorder.
Exclusion criteria
. Have received androgen therapy at any time during the past 3 months (during the past 7 months if therapy was an investigational implantable product)
. Be experiencing any chronic or acute life stress relating to any major life change
. Be experiencing depression and/or receiving medication for such illness or disorder
. Have current severe skin problems (such as severe or cystic acne) or allergy to adhesives (like the ones in bandages)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
To assess the efficacy of testosterone transdermal system (TS) as measured by the change from baseline in the frequency of total satisfying sexual activity captured by the Sexual Activity Log (SAL).
. Have had a major illness, active gall bladder disease, or gynecological or breast surgery within the last 6 months
. Have a history of breast, endometrial, or other gynecological cancer at any time before study participation or other cancer within the last 5 years
. Have diabetes, a history of cerebrovascular disease, thromboembolic disorders, heart attack, or angina at any time before study participation or thrombophlebitis within the last 5 years
. Have abnormal laboratory test results upon initial screening for this study